Organization
Hospital de la Santa Creu i Sant Pau
25 abstracts
Abstract
Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).Org: Medical Oncology, Yale School of Medicine, Yale Cancer Center, Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma.Org: Medical Oncology Department, Institute of Biomedicine of Seville, Hospital Universitario y Politécnico La Fe, Son Espases University Hospital, University Hospital Virgen del Rocio,
Abstract
A phase III randomized trial of neo-adjuvant chemotherapy in high-risk soft tissue sarcoma (ISG-STS 1001): Feasibility and activity of concurrent chemotherapy and radiation therapy.Org: Fondazione IRCCS Istituto Nazionale dei Tumori, IRCCS Fondazione Istituto Nazionale dei Tumori di Milano, Humanitas Clinical Institute, Candiolo Cancer Institute, Centre Léon Bérard,
Abstract
Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial.Org: Department of Experimental Oncology, Milano, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Vall d'Hebron University Hospital, Bergonié Institute,
Abstract
ImmunoSarc II master trial (phase II of sunitinib and nivolumab): Results from the dedifferentiated chondrosarcoma (DDCS) cohort—A GEIS, ISG and UCL study.Org: University College London Hospital NHS Trust and Great Ormond Street Hospital, Health Research Institute-Fundación Jiménez Díaz University Hospital, Autonomous University of Madrid (IIS-FJD, UAM), IRCCS Istituto Ortopedico Rizzoli, Hospital Universitario Miguel Servet,
Abstract
Comprehensive clinical characteristics and ctDNA mutational profile analysis of endocrine resistance/sensitivity to adjuvant ET therapy in luminal breast cancer from the GEICAM/2014-03_RegistEM registry.Org: Instituto Valenciano de Oncología (IVO), GEICAM Spanish Breast Cancer Group, Hospital Universitario de Donostia-BioDonostia, Complejo Hospitalario Universitario a Coruña (CHUAC), Hospital Universitario de Canarias,
Abstract
KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.Org: Candiolo Cancer Institute, FPO-IRCCS, IOR, Dexeus University Hospital, IRCCS Azienda Ospedaliero Universitaria Bologna,
Abstract
Clinical applicability of guideline-recommended molecular targets and genome-targeted cancer therapies.Org: Hospital de la Santa Creu i Sant Pau, Brigham and Women's Hospital, Brigham and Women's Hospital and Harvard Medical School,
Abstract
Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial.Org: Memorial Sloan Kettering Cancer Center, Royal Marsden NHS Foundation Trust, The Christie NHS Foundation Trust and University of Manchester, University of Pittsburgh Medical Center (UPMC), Duke Cancer Institute,
Abstract
Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).Org: Klinik für Pneumologie - Evangelische Lungenklinik Berlin Buch, Berlin, Germany, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, Federal State Budgetary Institution “N. N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation, Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy,
Abstract
Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.Org: Memorial Sloan Kettering Cancer Center, Chris O'Brien Lifehouse, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Medical Oncology and Sarcoma Center, Dana-Farber Cancer Institute,
Abstract
Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.Org: Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario Son Espases, Hospital Arnau de Vilanova; GEICAM Spanish Breast Cancer Group,
Abstract
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.Org: Early Phase Clinical Trials Unit, START Madrid Fundacion Jimenez Diaz, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), University College London Hospital NHS Trust and Great Ormond Street Hospital,
Abstract
Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.Org: Wilmot Cancer Institute, University of Rochester Medical Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, City of Hope Comprehensive Cancer Center, University of Texas MD Anderson Cancer Center,
Abstract
ctDNA mutational profiles in luminal breast cancer with early vs late distant relapse: Geicam/2014-03.Org: Fundación Instituto Valenciano de Oncología (FIVO), GEICAM Spanish Breast Cancer Group, Valencia, Spain, GEICAM Spanish Breast Cancer Group, Barcelona, Spain, Hospital Universitario de Donostia-BioDonostia, Hospital de la Santa Creu i Sant Pau, Hospital Universitario de Canarias,
Abstract
Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast).Org: Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)–H. Universitario Reina Sofía, Universidad de Córdoba, H. Universitario Reina Sofía, Universidad de Córdoba, Hospital Universitario Miguel Servet, CIBERONC-ISCIII,
Abstract
Upfront vs deferred monoclonal antibodies in metastatic colorectal cancer: A target trial emulation using the GEMCAD 14-01 prospective cohort.Org: Hospital Clínic Barcelona, Antwerp University Hospital, Hospital Univ. Miguel Servet, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Complejo Hospitalario Universitario Ourense,
Abstract
Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: Pooled analysis of 10 clinical trials.Org: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, CLL Center, Dana-Farber Cancer Institute,
Abstract
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: Results from the observational study GEM1801.Org: Hospital Universitario San Pedro de Alcántara, Unidad Intercentros de Oncología, Hospitales Universitarios Regional y Virgen de la Victoria (HURyVV), Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Universitari Vall d’Hebron y Vall Hebrón Institute of Oncology (VHIO),
Abstract
Multicenter analysis of melanoma recurrence pattern and management after adjuvant immunotherapy.Org: Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Hospital de la Santa Creu i Sant Pau, Hospital Universitario San Cecilio, Catalan Institute of Oncology (ICO), ICO Hospital Germans Trias i Pujol, Badalona, Spain,
Abstract
Real-world evidence analysis of early-stage prostate cancer using natural language processing.Org: Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital/VHIO, University Hospital La Fe, SERVICIO DE ONCOLOGIA MEDICA, Hospital de la Santa Creu i Sant Pau,
Abstract
Outcomes and safety of subsequent treatments after immune- and anti-VEGF therapy in patients with metastatic clear-cell renal cell carcinoma: Outcomes from a tertiary referral hospital.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barts Cancer Institute, Barts Health NHS Trust and the Royal Free NHS Foundation Trust,
Abstract
A NEW ASSOCIATION OF LILRB1 POLYMORPHISM WITH RA IN CAUCASIAN POPULATIONOrg: Immunology and Combinations, GlaxoSmithKline, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Hospital de Sant Pau, Rheumatology, Barcelona, Spain,
Abstract
BIOMARKERS IN JUVENILE IDIOPATIC ARTHRITIS: DESCRIPTION OF GROUPS WITH DIFFERENT DEGREES OF DISCREPANCY BETWEEN SERUM CALPROTECTIN AND C-REACTIVE PROTEIN.Org: Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona,
Abstract
ASSOCIATION STUDY OF GENETIC RISK VARIANTS FOR PSORIASIS IN A LARGE COHORT OF PSORIATIC ARTHRITIS, PSORIASIS AND CONTROLS OF THE SPANISH POPULATION AND ASSOCIATION WITH RELEVANT CLINICAL SUBPHENOTYPES Org: Hospital Clinic i Provincial de Barcelona, Barcelona, Spain, Hospital Universitario Gregorio Marañόn, Madrid, Complejo Hospitalario Juan Canalejo, A Coruña, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, Hospital Universitario de Salamanca, Salamanca,